[Clinical assessment of drug safety].
The environment of drug safety is changing. In addition to the current system of pharmacovigilance based on spontaneous report of adverse events, clinical data observed in a given patient with a given symptom is taken into consideration and compared with information coming from pharmacovigilance data bases, which is then analyzed for causality by the experts of both the promotor and the public network. Such information is integrated into a risk management strategy, defined together by the French drug agency (Afssaps) and the marketing authorization holder. This strategy includes a pharmacovigilance plan and, if possible, a risk minimisation plan.
Imbs
J-L
JL
Centre régional de pharmacovigilance d'Alsace, Hôpital civil, 1, place de l'Hôpital, F 67000 Strasbourg. jean-louis.imbs@pharmaco-ulp.u-strasbg.fr
Welsch
M
M
D035843:Biomedical Research; D016208:Databases, Factual; D064420:Drug-Related Side Effects and Adverse Reactions; D005602:France; D006801:Humans; D011358:Product Surveillance, Postmarketing; D012308:Risk Management